 Douglas Seals
Concepts (756)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aging | 198 | 2025 | 1785 | 22.220 |
Why?
| | Endothelium, Vascular | 85 | 2025 | 926 | 15.660 |
Why?
| | Vascular Stiffness | 42 | 2024 | 480 | 9.370 |
Why?
| | Oxidative Stress | 64 | 2025 | 1239 | 8.820 |
Why?
| | Exercise | 101 | 2024 | 1941 | 8.560 |
Why?
| | Vasodilation | 61 | 2025 | 481 | 8.060 |
Why?
| | Arteries | 33 | 2024 | 269 | 6.780 |
Why?
| | Brachial Artery | 39 | 2025 | 206 | 6.330 |
Why?
| | Sympathetic Nervous System | 67 | 2023 | 185 | 6.270 |
Why?
| | Blood Pressure | 104 | 2023 | 1753 | 6.240 |
Why?
| | Writing | 8 | 2024 | 95 | 4.840 |
Why?
| | Biomedical Research | 11 | 2024 | 658 | 4.660 |
Why?
| | Carotid Arteries | 28 | 2024 | 207 | 4.380 |
Why?
| | Aorta | 18 | 2024 | 416 | 3.920 |
Why?
| | Vascular Diseases | 15 | 2023 | 243 | 3.830 |
Why?
| | Antioxidants | 24 | 2023 | 562 | 3.540 |
Why?
| | Regional Blood Flow | 36 | 2020 | 463 | 3.410 |
Why?
| | Nitric Oxide | 33 | 2023 | 896 | 3.400 |
Why?
| | Cardiovascular Diseases | 28 | 2023 | 2028 | 3.210 |
Why?
| | Physiology | 5 | 2024 | 13 | 3.210 |
Why?
| | Physical Endurance | 48 | 2016 | 269 | 3.200 |
Why?
| | Sodium Nitrite | 8 | 2021 | 39 | 3.120 |
Why?
| | Publishing | 5 | 2023 | 141 | 3.090 |
Why?
| | Heart Rate | 84 | 2023 | 813 | 3.070 |
Why?
| | Endothelial Cells | 21 | 2025 | 744 | 2.900 |
Why?
| | Resistance Training | 5 | 2023 | 152 | 2.840 |
Why?
| | Aged | 175 | 2025 | 22282 | 2.810 |
Why?
| | Postmenopause | 26 | 2025 | 370 | 2.790 |
Why?
| | Mitochondria | 10 | 2025 | 857 | 2.570 |
Why?
| | Hypertension | 23 | 2023 | 1245 | 2.540 |
Why?
| | Caloric Restriction | 10 | 2021 | 109 | 2.490 |
Why?
| | Middle Aged | 196 | 2025 | 31322 | 2.440 |
Why?
| | Blood Vessels | 6 | 2020 | 186 | 2.440 |
Why?
| | Dietary Supplements | 19 | 2023 | 534 | 2.370 |
Why?
| | Physical Exertion | 34 | 2014 | 215 | 2.320 |
Why?
| | Diet, Sodium-Restricted | 8 | 2020 | 36 | 2.280 |
Why?
| | Ascorbic Acid | 17 | 2025 | 123 | 2.190 |
Why?
| | Inflammation | 24 | 2024 | 2721 | 2.190 |
Why?
| | Male | 255 | 2025 | 63748 | 2.180 |
Why?
| | Humans | 345 | 2025 | 130305 | 2.150 |
Why?
| | Pulse Wave Analysis | 20 | 2023 | 253 | 2.140 |
Why?
| | Nitric Oxide Synthase Type III | 13 | 2020 | 206 | 2.130 |
Why?
| | Muscles | 32 | 2023 | 323 | 2.080 |
Why?
| | Physical Fitness | 20 | 2013 | 203 | 2.070 |
Why?
| | Baroreflex | 16 | 2016 | 61 | 2.030 |
Why?
| | Physical Conditioning, Animal | 10 | 2021 | 229 | 2.000 |
Why?
| | Oxygen Consumption | 47 | 2023 | 680 | 1.990 |
Why?
| | Cardiovascular Physiological Phenomena | 13 | 2019 | 44 | 1.970 |
Why?
| | Exercise Tolerance | 8 | 2023 | 270 | 1.940 |
Why?
| | Methylamines | 5 | 2022 | 31 | 1.920 |
Why?
| | NF-kappa B | 9 | 2015 | 691 | 1.920 |
Why?
| | Peer Review | 4 | 2023 | 47 | 1.910 |
Why?
| | Superoxides | 16 | 2022 | 201 | 1.910 |
Why?
| | Vasodilator Agents | 12 | 2024 | 325 | 1.870 |
Why?
| | Acetylcholine | 12 | 2023 | 185 | 1.760 |
Why?
| | Adult | 202 | 2025 | 35711 | 1.660 |
Why?
| | Animals | 83 | 2024 | 35076 | 1.630 |
Why?
| | Norepinephrine | 29 | 2011 | 218 | 1.630 |
Why?
| | Mice | 52 | 2024 | 16832 | 1.620 |
Why?
| | Diet, Western | 3 | 2022 | 79 | 1.600 |
Why?
| | Female | 176 | 2025 | 68842 | 1.570 |
Why?
| | Adipose Tissue | 19 | 2018 | 593 | 1.560 |
Why?
| | Heart | 16 | 2018 | 654 | 1.550 |
Why?
| | Healthy Aging | 4 | 2024 | 33 | 1.510 |
Why?
| | Vascular Resistance | 20 | 2012 | 373 | 1.450 |
Why?
| | Motor Activity | 8 | 2024 | 670 | 1.420 |
Why?
| | Respiratory Muscles | 5 | 2023 | 32 | 1.390 |
Why?
| | Salicylates | 5 | 2015 | 30 | 1.390 |
Why?
| | Mice, Inbred C57BL | 26 | 2024 | 5365 | 1.390 |
Why?
| | Forearm | 18 | 2023 | 119 | 1.380 |
Why?
| | NADPH Oxidases | 13 | 2020 | 109 | 1.370 |
Why?
| | Cellular Senescence | 6 | 2023 | 177 | 1.300 |
Why?
| | Research Personnel | 4 | 2023 | 162 | 1.290 |
Why?
| | Autonomic Nervous System | 11 | 2008 | 75 | 1.290 |
Why?
| | Reactive Oxygen Species | 14 | 2025 | 587 | 1.250 |
Why?
| | Estrogens | 8 | 2023 | 355 | 1.220 |
Why?
| | Age Factors | 28 | 2024 | 3153 | 1.220 |
Why?
| | Tyrosine | 14 | 2020 | 220 | 1.180 |
Why?
| | Vasoconstriction | 7 | 2017 | 195 | 1.180 |
Why?
| | Healthy Lifestyle | 2 | 2018 | 32 | 1.170 |
Why?
| | Double-Blind Method | 15 | 2023 | 1878 | 1.150 |
Why?
| | Aorta, Thoracic | 4 | 2014 | 262 | 1.130 |
Why?
| | Femoral Artery | 11 | 2013 | 176 | 1.110 |
Why?
| | Muscle, Skeletal | 21 | 2024 | 1642 | 1.100 |
Why?
| | Geriatrics | 4 | 2015 | 80 | 1.090 |
Why?
| | NAD | 5 | 2023 | 73 | 1.090 |
Why?
| | Smoking Water Pipes | 2 | 2023 | 8 | 1.070 |
Why?
| | Water Pipe Smoking | 2 | 2023 | 9 | 1.070 |
Why?
| | Estrogen Replacement Therapy | 12 | 2013 | 142 | 1.060 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 4 | 2015 | 345 | 1.040 |
Why?
| | Metabolomics | 4 | 2021 | 599 | 1.000 |
Why?
| | Receptors, Adrenergic, beta | 6 | 2008 | 127 | 0.990 |
Why?
| | Longevity | 4 | 2015 | 151 | 0.990 |
Why?
| | Inflammation Mediators | 5 | 2018 | 509 | 0.980 |
Why?
| | Cyclic N-Oxides | 8 | 2020 | 31 | 0.940 |
Why?
| | Bottle-Nosed Dolphin | 1 | 2024 | 3 | 0.930 |
Why?
| | Curcumin | 2 | 2017 | 30 | 0.930 |
Why?
| | Elasticity | 11 | 2017 | 202 | 0.920 |
Why?
| | Drinking Water | 2 | 2022 | 76 | 0.920 |
Why?
| | Interleukin-1 | 5 | 2022 | 973 | 0.910 |
Why?
| | Work-Life Balance | 1 | 2024 | 17 | 0.910 |
Why?
| | Habits | 7 | 2017 | 43 | 0.910 |
Why?
| | Cross-Over Studies | 10 | 2023 | 521 | 0.910 |
Why?
| | Gastrointestinal Microbiome | 3 | 2020 | 638 | 0.880 |
Why?
| | Trehalose | 4 | 2017 | 30 | 0.870 |
Why?
| | Career Choice | 2 | 2024 | 212 | 0.870 |
Why?
| | Body Composition | 30 | 2012 | 658 | 0.850 |
Why?
| | Physical Education and Training | 15 | 2024 | 76 | 0.850 |
Why?
| | Body Temperature Regulation | 7 | 2007 | 99 | 0.850 |
Why?
| | Compliance | 15 | 2017 | 50 | 0.840 |
Why?
| | Human Umbilical Vein Endothelial Cells | 3 | 2021 | 98 | 0.830 |
Why?
| | Fenofibrate | 2 | 2013 | 30 | 0.820 |
Why?
| | Young Adult | 29 | 2025 | 12404 | 0.820 |
Why?
| | Goals | 1 | 2024 | 165 | 0.820 |
Why?
| | Elastin | 6 | 2023 | 78 | 0.810 |
Why?
| | Vaping | 1 | 2023 | 57 | 0.810 |
Why?
| | Transcriptome | 3 | 2023 | 890 | 0.810 |
Why?
| | Lyases | 1 | 2022 | 9 | 0.800 |
Why?
| | Cardiorespiratory Fitness | 2 | 2021 | 52 | 0.800 |
Why?
| | Nicotinamide Mononucleotide | 3 | 2023 | 9 | 0.790 |
Why?
| | Hypolipidemic Agents | 2 | 2013 | 93 | 0.790 |
Why?
| | Sodium, Dietary | 4 | 2013 | 41 | 0.780 |
Why?
| | Muscle Strength | 6 | 2023 | 308 | 0.780 |
Why?
| | Research Design | 4 | 2022 | 1052 | 0.780 |
Why?
| | Electronic Nicotine Delivery Systems | 1 | 2023 | 91 | 0.780 |
Why?
| | Obesity | 14 | 2023 | 2869 | 0.770 |
Why?
| | Rest | 13 | 2007 | 123 | 0.770 |
Why?
| | Stress, Physiological | 12 | 2017 | 416 | 0.770 |
Why?
| | Speech | 1 | 2022 | 73 | 0.760 |
Why?
| | Hemodynamics | 17 | 2023 | 1099 | 0.760 |
Why?
| | Aortitis | 2 | 2011 | 10 | 0.750 |
Why?
| | Vagus Nerve | 7 | 2005 | 86 | 0.750 |
Why?
| | Spirostans | 1 | 2021 | 4 | 0.750 |
Why?
| | Breathing Exercises | 1 | 2021 | 20 | 0.740 |
Why?
| | Inhalation | 1 | 2021 | 30 | 0.740 |
Why?
| | Spin Labels | 8 | 2020 | 46 | 0.740 |
Why?
| | Leg | 14 | 2007 | 242 | 0.740 |
Why?
| | Models, Animal | 6 | 2024 | 373 | 0.730 |
Why?
| | Running | 16 | 2017 | 229 | 0.720 |
Why?
| | Superoxide Dismutase | 9 | 2016 | 330 | 0.710 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2021 | 1210 | 0.710 |
Why?
| | Autophagy | 3 | 2017 | 269 | 0.710 |
Why?
| | Comprehension | 1 | 2022 | 169 | 0.710 |
Why?
| | Reference Values | 26 | 2021 | 793 | 0.700 |
Why?
| | Frailty | 2 | 2024 | 150 | 0.700 |
Why?
| | Isometric Contraction | 14 | 1996 | 186 | 0.700 |
Why?
| | Life Style | 14 | 2017 | 461 | 0.690 |
Why?
| | Cardiac Output | 15 | 2004 | 159 | 0.690 |
Why?
| | Doxorubicin | 2 | 2021 | 321 | 0.680 |
Why?
| | Fasting | 2 | 2020 | 265 | 0.680 |
Why?
| | Cytokines | 10 | 2019 | 2016 | 0.680 |
Why?
| | Nitroglycerin | 3 | 2020 | 19 | 0.670 |
Why?
| | Dementia | 1 | 2023 | 230 | 0.670 |
Why?
| | Biomarkers | 18 | 2023 | 3923 | 0.670 |
Why?
| | Niacinamide | 3 | 2022 | 73 | 0.650 |
Why?
| | Lipids | 6 | 2018 | 627 | 0.650 |
Why?
| | Spermidine | 2 | 2024 | 17 | 0.640 |
Why?
| | Nitrites | 3 | 2014 | 81 | 0.640 |
Why?
| | Overweight | 3 | 2009 | 526 | 0.640 |
Why?
| | Mentoring | 1 | 2021 | 126 | 0.630 |
Why?
| | Physical Conditioning, Human | 1 | 2019 | 39 | 0.630 |
Why?
| | Adolescent | 46 | 2023 | 20374 | 0.630 |
Why?
| | Isoproterenol | 4 | 2007 | 111 | 0.630 |
Why?
| | Sex Characteristics | 13 | 2011 | 728 | 0.630 |
Why?
| | Energy Metabolism | 9 | 2007 | 841 | 0.630 |
Why?
| | Cardiovascular System | 10 | 2020 | 139 | 0.620 |
Why?
| | Sirtuin 1 | 3 | 2016 | 30 | 0.610 |
Why?
| | Adrenergic beta-Agonists | 4 | 2007 | 132 | 0.610 |
Why?
| | Adaptation, Physiological | 8 | 2019 | 516 | 0.610 |
Why?
| | Amino Acids | 2 | 2019 | 474 | 0.600 |
Why?
| | Health Status | 3 | 2019 | 756 | 0.590 |
Why?
| | Body Constitution | 4 | 2005 | 53 | 0.580 |
Why?
| | Lipoproteins, LDL | 10 | 2023 | 132 | 0.580 |
Why?
| | Blood Volume | 8 | 1998 | 61 | 0.580 |
Why?
| | Glycation End Products, Advanced | 3 | 2013 | 63 | 0.580 |
Why?
| | Sodium Chloride, Dietary | 3 | 2019 | 37 | 0.570 |
Why?
| | Muscle, Smooth, Vascular | 6 | 2017 | 437 | 0.560 |
Why?
| | Tunica Intima | 7 | 2006 | 86 | 0.560 |
Why?
| | Diet | 6 | 2024 | 1214 | 0.560 |
Why?
| | Nitroprusside | 5 | 2011 | 67 | 0.550 |
Why?
| | Extracellular Matrix | 1 | 2021 | 500 | 0.540 |
Why?
| | Serine | 2 | 2015 | 137 | 0.540 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2022 | 2074 | 0.530 |
Why?
| | Transcription Factor RelA | 4 | 2011 | 85 | 0.530 |
Why?
| | Diet Therapy | 1 | 2016 | 37 | 0.530 |
Why?
| | Glucose | 4 | 2019 | 989 | 0.530 |
Why?
| | Basal Metabolism | 4 | 2004 | 57 | 0.530 |
Why?
| | Muscle Contraction | 13 | 2003 | 427 | 0.520 |
Why?
| | Epinephrine | 14 | 2007 | 180 | 0.520 |
Why?
| | Time Factors | 21 | 2021 | 6615 | 0.520 |
Why?
| | Primary Prevention | 1 | 2018 | 193 | 0.510 |
Why?
| | Estradiol | 3 | 2021 | 498 | 0.500 |
Why?
| | Renal Insufficiency, Chronic | 5 | 2023 | 573 | 0.500 |
Why?
| | Premenopause | 9 | 2025 | 127 | 0.500 |
Why?
| | Cross-Sectional Studies | 22 | 2020 | 5083 | 0.480 |
Why?
| | Blood Glucose | 10 | 2017 | 2100 | 0.480 |
Why?
| | Body Mass Index | 18 | 2015 | 2268 | 0.470 |
Why?
| | Collagen | 3 | 2021 | 437 | 0.470 |
Why?
| | Risk Factors | 19 | 2021 | 9865 | 0.470 |
Why?
| | Heterocyclic Compounds, 4 or More Rings | 1 | 2014 | 19 | 0.470 |
Why?
| | Reflex | 6 | 2001 | 68 | 0.460 |
Why?
| | AMP-Activated Protein Kinases | 3 | 2017 | 190 | 0.460 |
Why?
| | Endothelium | 1 | 2014 | 116 | 0.450 |
Why?
| | Ubiquinone | 1 | 2014 | 28 | 0.450 |
Why?
| | Geriatric Assessment | 2 | 2015 | 203 | 0.450 |
Why?
| | Proteome | 1 | 2018 | 433 | 0.450 |
Why?
| | Nitrates | 4 | 2022 | 87 | 0.440 |
Why?
| | Niacin | 1 | 2013 | 19 | 0.440 |
Why?
| | Bufanolides | 1 | 2013 | 4 | 0.440 |
Why?
| | Hindlimb | 1 | 2014 | 127 | 0.430 |
Why?
| | Vitamin B Complex | 1 | 2013 | 41 | 0.430 |
Why?
| | Atherosclerosis | 1 | 2018 | 407 | 0.430 |
Why?
| | Organophosphorus Compounds | 1 | 2014 | 78 | 0.420 |
Why?
| | Locomotion | 1 | 2014 | 98 | 0.420 |
Why?
| | Eating | 2 | 2007 | 368 | 0.420 |
Why?
| | Aortic Diseases | 1 | 2014 | 115 | 0.410 |
Why?
| | Risk Reduction Behavior | 1 | 2014 | 212 | 0.410 |
Why?
| | Hand Strength | 3 | 2023 | 113 | 0.410 |
Why?
| | Exercise Test | 12 | 2021 | 622 | 0.410 |
Why?
| | Nitric Oxide Donors | 1 | 2012 | 18 | 0.400 |
Why?
| | Arm | 7 | 2008 | 109 | 0.400 |
Why?
| | Ganglionic Blockers | 7 | 2008 | 7 | 0.400 |
Why?
| | Repetitive Sequences, Nucleic Acid | 2 | 2024 | 113 | 0.400 |
Why?
| | Carotid Artery Diseases | 2 | 2010 | 65 | 0.390 |
Why?
| | Cognition | 2 | 2020 | 1110 | 0.390 |
Why?
| | Obesity, Abdominal | 1 | 2012 | 48 | 0.390 |
Why?
| | Allopurinol | 2 | 2016 | 61 | 0.390 |
Why?
| | Dose-Response Relationship, Drug | 8 | 2015 | 1983 | 0.380 |
Why?
| | Pressoreceptors | 6 | 2001 | 21 | 0.380 |
Why?
| | I-kappa B Proteins | 2 | 2009 | 77 | 0.370 |
Why?
| | Neurodegenerative Diseases | 2 | 2023 | 110 | 0.370 |
Why?
| | Adrenal Glands | 3 | 2000 | 73 | 0.370 |
Why?
| | Postural Balance | 1 | 2014 | 208 | 0.370 |
Why?
| | Arteritis | 1 | 2011 | 27 | 0.370 |
Why?
| | Ultrasonography | 11 | 2017 | 731 | 0.360 |
Why?
| | C-Reactive Protein | 3 | 2022 | 396 | 0.360 |
Why?
| | Oxidants | 1 | 2011 | 109 | 0.350 |
Why?
| | Systole | 6 | 2020 | 191 | 0.350 |
Why?
| | Colorado | 6 | 2024 | 4471 | 0.350 |
Why?
| | Uric Acid | 1 | 2012 | 162 | 0.350 |
Why?
| | Behavior, Animal | 1 | 2014 | 491 | 0.350 |
Why?
| | Athletic Performance | 2 | 2012 | 77 | 0.350 |
Why?
| | Cholesterol, LDL | 5 | 2008 | 361 | 0.350 |
Why?
| | Forkhead Transcription Factors | 1 | 2011 | 183 | 0.340 |
Why?
| | Analysis of Variance | 7 | 2011 | 1291 | 0.330 |
Why?
| | Athletes | 2 | 2022 | 411 | 0.330 |
Why?
| | Metabolome | 3 | 2018 | 320 | 0.330 |
Why?
| | Exercise Therapy | 7 | 2002 | 416 | 0.330 |
Why?
| | Antineoplastic Agents | 1 | 2021 | 2078 | 0.330 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2010 | 163 | 0.330 |
Why?
| | Hot Temperature | 5 | 1993 | 366 | 0.320 |
Why?
| | Peroxidase | 1 | 2010 | 183 | 0.320 |
Why?
| | Receptors, Adrenergic, beta-2 | 2 | 2007 | 45 | 0.320 |
Why?
| | Extremities | 2 | 2001 | 130 | 0.320 |
Why?
| | Biological Availability | 4 | 2021 | 131 | 0.320 |
Why?
| | Interleukins | 2 | 2022 | 247 | 0.310 |
Why?
| | Blood Circulation | 4 | 2021 | 41 | 0.310 |
Why?
| | Interleukin-6 | 4 | 2024 | 730 | 0.310 |
Why?
| | Anti-Bacterial Agents | 1 | 2019 | 1712 | 0.310 |
Why?
| | Administration, Oral | 5 | 2015 | 788 | 0.300 |
Why?
| | Vitamin D Deficiency | 1 | 2010 | 180 | 0.300 |
Why?
| | Energy Intake | 6 | 2020 | 454 | 0.300 |
Why?
| | Vitamin D | 2 | 2017 | 386 | 0.300 |
Why?
| | Oxygen | 11 | 2022 | 919 | 0.300 |
Why?
| | Healthy Volunteers | 3 | 2018 | 204 | 0.300 |
Why?
| | Collagen Type I | 3 | 2014 | 120 | 0.300 |
Why?
| | Upper Extremity | 1 | 2009 | 96 | 0.300 |
Why?
| | Cells, Cultured | 5 | 2025 | 4106 | 0.300 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 1 | 2008 | 42 | 0.300 |
Why?
| | NG-Nitroarginine Methyl Ester | 4 | 2013 | 46 | 0.300 |
Why?
| | Leukocytes, Mononuclear | 1 | 2011 | 550 | 0.300 |
Why?
| | Signal Transduction | 6 | 2014 | 4930 | 0.300 |
Why?
| | Peroneal Nerve | 5 | 2000 | 19 | 0.300 |
Why?
| | Endothelin-1 | 2 | 2009 | 181 | 0.300 |
Why?
| | Posture | 6 | 2001 | 175 | 0.300 |
Why?
| | Ventricular Function, Left | 3 | 2003 | 530 | 0.300 |
Why?
| | Abdomen | 5 | 2004 | 116 | 0.290 |
Why?
| | Sports | 5 | 2003 | 226 | 0.290 |
Why?
| | Hypercapnia | 2 | 2025 | 56 | 0.280 |
Why?
| | Phosphorylation | 6 | 2013 | 1709 | 0.280 |
Why?
| | Infusions, Intravenous | 5 | 2014 | 395 | 0.280 |
Why?
| | Adiposity | 1 | 2012 | 507 | 0.280 |
Why?
| | Human Experimentation | 1 | 2007 | 12 | 0.280 |
Why?
| | Regression Analysis | 10 | 2011 | 991 | 0.280 |
Why?
| | Acetophenones | 3 | 2019 | 13 | 0.280 |
Why?
| | Trimethaphan | 5 | 2005 | 5 | 0.270 |
Why?
| | Enzyme Inhibitors | 4 | 2016 | 832 | 0.270 |
Why?
| | Pilot Projects | 3 | 2020 | 1565 | 0.270 |
Why?
| | Swimming | 5 | 2002 | 47 | 0.270 |
Why?
| | Phenylephrine | 5 | 2005 | 75 | 0.270 |
Why?
| | Electrocardiography | 9 | 2005 | 615 | 0.270 |
Why?
| | Tunica Media | 3 | 2001 | 38 | 0.270 |
Why?
| | Hypoxia | 6 | 1999 | 1075 | 0.260 |
Why?
| | Treatment Outcome | 6 | 2021 | 10341 | 0.260 |
Why?
| | Proteins | 3 | 2009 | 948 | 0.260 |
Why?
| | Nitric Oxide Synthase | 3 | 2014 | 238 | 0.260 |
Why?
| | Gene Expression Regulation | 3 | 2017 | 2549 | 0.260 |
Why?
| | Fatty Acids | 2 | 2019 | 416 | 0.260 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2008 | 533 | 0.250 |
Why?
| | Microcirculation | 2 | 2019 | 142 | 0.250 |
Why?
| | Brain | 6 | 2023 | 2629 | 0.250 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2007 | 290 | 0.250 |
Why?
| | Recovery of Function | 4 | 2017 | 646 | 0.250 |
Why?
| | Thermogenesis | 1 | 2005 | 44 | 0.250 |
Why?
| | Cell Nucleus | 1 | 2008 | 580 | 0.240 |
Why?
| | Receptors, Adrenergic, alpha | 2 | 2002 | 31 | 0.240 |
Why?
| | Carbon Dioxide | 3 | 2023 | 262 | 0.240 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 2 | 2011 | 42 | 0.240 |
Why?
| | MicroRNAs | 1 | 2011 | 680 | 0.240 |
Why?
| | Carotid Artery, Internal | 1 | 2025 | 41 | 0.240 |
Why?
| | Arginine | 1 | 2006 | 264 | 0.240 |
Why?
| | American Heart Association | 2 | 2020 | 311 | 0.230 |
Why?
| | Preventive Medicine | 2 | 2015 | 40 | 0.230 |
Why?
| | Veins | 5 | 2009 | 60 | 0.230 |
Why?
| | Apigenin | 1 | 2023 | 2 | 0.220 |
Why?
| | Flavonols | 1 | 2023 | 11 | 0.220 |
Why?
| | Weight Loss | 2 | 2008 | 728 | 0.220 |
Why?
| | Respiratory Therapy | 1 | 2023 | 23 | 0.220 |
Why?
| | Skin | 4 | 2019 | 742 | 0.220 |
Why?
| | Lactates | 7 | 2007 | 83 | 0.210 |
Why?
| | History, 21st Century | 1 | 2024 | 184 | 0.210 |
Why?
| | Xanthine Oxidase | 3 | 2009 | 80 | 0.210 |
Why?
| | Blueberry Plants | 1 | 2023 | 4 | 0.210 |
Why?
| | Tissue Culture Techniques | 2 | 2014 | 71 | 0.210 |
Why?
| | History, 20th Century | 1 | 2024 | 297 | 0.210 |
Why?
| | Hand | 8 | 1994 | 152 | 0.210 |
Why?
| | Drug Evaluation, Preclinical | 2 | 2014 | 174 | 0.210 |
Why?
| | Blood Flow Velocity | 6 | 2019 | 413 | 0.200 |
Why?
| | Cholesterol | 5 | 1997 | 407 | 0.200 |
Why?
| | Aged, 80 and over | 12 | 2023 | 7128 | 0.200 |
Why?
| | Fibrinolysis | 2 | 2008 | 136 | 0.200 |
Why?
| | Anthropometry | 3 | 2011 | 206 | 0.200 |
Why?
| | Myocardium | 5 | 2010 | 989 | 0.200 |
Why?
| | Authorship | 1 | 2023 | 45 | 0.200 |
Why?
| | Cold Temperature | 7 | 2001 | 151 | 0.200 |
Why?
| | Apoptosis | 1 | 2011 | 2519 | 0.200 |
Why?
| | Acetylene | 2 | 2003 | 3 | 0.200 |
Why?
| | Supine Position | 6 | 1999 | 38 | 0.200 |
Why?
| | Terminology as Topic | 1 | 2023 | 204 | 0.200 |
Why?
| | Sugars | 1 | 2022 | 37 | 0.200 |
Why?
| | Adrenal Medulla | 1 | 2002 | 7 | 0.200 |
Why?
| | Respiration | 7 | 1998 | 192 | 0.190 |
Why?
| | Coronary Disease | 6 | 1998 | 392 | 0.190 |
Why?
| | Citrulline | 1 | 2022 | 44 | 0.190 |
Why?
| | Sirolimus | 3 | 2021 | 197 | 0.190 |
Why?
| | Universities | 1 | 2024 | 406 | 0.190 |
Why?
| | Body Weight | 10 | 2019 | 938 | 0.190 |
Why?
| | Case-Control Studies | 3 | 2020 | 3369 | 0.190 |
Why?
| | Insulin | 11 | 2022 | 2322 | 0.190 |
Why?
| | Cyclooxygenase 2 | 2 | 2014 | 176 | 0.180 |
Why?
| | Nicotine | 1 | 2023 | 304 | 0.180 |
Why?
| | Fatty Liver | 1 | 2023 | 232 | 0.180 |
Why?
| | Progesterone | 1 | 2002 | 244 | 0.180 |
Why?
| | I-kappa B Kinase | 2 | 2011 | 53 | 0.180 |
Why?
| | Weight Gain | 1 | 2004 | 508 | 0.180 |
Why?
| | Free Radical Scavengers | 2 | 2013 | 82 | 0.180 |
Why?
| | Extracellular Vesicles | 1 | 2022 | 130 | 0.180 |
Why?
| | Manuscripts as Topic | 1 | 2000 | 2 | 0.180 |
Why?
| | Knee | 1 | 2000 | 61 | 0.170 |
Why?
| | Mexican Americans | 1 | 2001 | 113 | 0.170 |
Why?
| | DNA Transposable Elements | 1 | 2021 | 120 | 0.170 |
Why?
| | DNA Methylation | 2 | 2024 | 610 | 0.170 |
Why?
| | Lipocalin-2 | 1 | 2020 | 77 | 0.170 |
Why?
| | Lung | 4 | 1999 | 3967 | 0.170 |
Why?
| | Fibrinogen | 2 | 1998 | 159 | 0.170 |
Why?
| | Myocardial Reperfusion Injury | 2 | 2011 | 126 | 0.170 |
Why?
| | RNA, Untranslated | 1 | 2021 | 114 | 0.170 |
Why?
| | Mentors | 1 | 2021 | 174 | 0.170 |
Why?
| | Triglycerides | 4 | 2017 | 525 | 0.160 |
Why?
| | Drug Monitoring | 1 | 2021 | 194 | 0.160 |
Why?
| | Functional Food | 1 | 2019 | 2 | 0.160 |
Why?
| | Kidney | 6 | 2017 | 1343 | 0.160 |
Why?
| | Pulmonary Circulation | 1 | 2001 | 430 | 0.160 |
Why?
| | Waist-Hip Ratio | 2 | 2012 | 36 | 0.160 |
Why?
| | Rats | 11 | 2015 | 5285 | 0.160 |
Why?
| | Adrenergic alpha-Agonists | 3 | 2005 | 30 | 0.160 |
Why?
| | Adipose Tissue, White | 1 | 2019 | 38 | 0.160 |
Why?
| | Menopause | 2 | 2006 | 303 | 0.160 |
Why?
| | Fluorescent Antibody Technique | 3 | 2009 | 393 | 0.160 |
Why?
| | Adipokines | 1 | 2019 | 46 | 0.160 |
Why?
| | Transforming Growth Factor beta | 2 | 2012 | 465 | 0.160 |
Why?
| | NF-KappaB Inhibitor alpha | 2 | 2009 | 49 | 0.160 |
Why?
| | Lower Body Negative Pressure | 4 | 1992 | 22 | 0.150 |
Why?
| | Social Class | 1 | 2001 | 258 | 0.150 |
Why?
| | Stroke Volume | 7 | 1998 | 593 | 0.150 |
Why?
| | Guidelines as Topic | 1 | 2020 | 262 | 0.150 |
Why?
| | Linear Models | 2 | 2012 | 826 | 0.150 |
Why?
| | Cohort Studies | 5 | 2013 | 5431 | 0.150 |
Why?
| | Metabolic Syndrome | 2 | 2019 | 341 | 0.150 |
Why?
| | Pyridinium Compounds | 1 | 2018 | 24 | 0.150 |
Why?
| | Leptin | 5 | 2019 | 218 | 0.150 |
Why?
| | Adipocytes | 1 | 2019 | 204 | 0.140 |
Why?
| | Methionine | 1 | 2018 | 159 | 0.140 |
Why?
| | Cardiology | 1 | 2020 | 281 | 0.140 |
Why?
| | Unfolded Protein Response | 2 | 2017 | 52 | 0.140 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 1997 | 152 | 0.140 |
Why?
| | Calcitriol | 1 | 2017 | 56 | 0.140 |
Why?
| | Cholecalciferol | 1 | 2017 | 59 | 0.140 |
Why?
| | Neuromuscular Junction | 2 | 1995 | 57 | 0.140 |
Why?
| | Stress, Psychological | 3 | 1995 | 1058 | 0.140 |
Why?
| | Carotid Artery, Common | 1 | 2017 | 37 | 0.130 |
Why?
| | Heart Conduction System | 4 | 2002 | 94 | 0.130 |
Why?
| | Congresses as Topic | 1 | 2018 | 218 | 0.130 |
Why?
| | Hyperuricemia | 1 | 2016 | 45 | 0.130 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2017 | 101 | 0.130 |
Why?
| | Education, Graduate | 1 | 2016 | 35 | 0.130 |
Why?
| | Cognitive Dysfunction | 1 | 2021 | 346 | 0.130 |
Why?
| | Students, Health Occupations | 1 | 2016 | 28 | 0.130 |
Why?
| | Insulin Resistance | 3 | 2018 | 1167 | 0.130 |
Why?
| | Blood Coagulation | 1 | 1998 | 234 | 0.130 |
Why?
| | Walking | 3 | 2011 | 502 | 0.130 |
Why?
| | Gene Regulatory Networks | 1 | 2018 | 283 | 0.130 |
Why?
| | Age Distribution | 1 | 1997 | 379 | 0.130 |
Why?
| | Methemoglobin | 1 | 2015 | 20 | 0.130 |
Why?
| | Hemostasis | 2 | 1998 | 70 | 0.130 |
Why?
| | Risk Assessment | 2 | 2018 | 3310 | 0.130 |
Why?
| | Program Development | 1 | 2018 | 363 | 0.120 |
Why?
| | Myocardial Contraction | 3 | 1988 | 337 | 0.120 |
Why?
| | Anaerobic Threshold | 3 | 2008 | 27 | 0.120 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 1995 | 53 | 0.120 |
Why?
| | Lipid Metabolism | 1 | 2018 | 496 | 0.120 |
Why?
| | NADPH Oxidase 4 | 1 | 2014 | 8 | 0.120 |
Why?
| | Urinalysis | 1 | 2015 | 73 | 0.120 |
Why?
| | Src Homology 2 Domain-Containing, Transforming Protein 1 | 1 | 2014 | 12 | 0.120 |
Why?
| | Shc Signaling Adaptor Proteins | 1 | 2014 | 12 | 0.120 |
Why?
| | Rotenone | 1 | 2014 | 10 | 0.120 |
Why?
| | Skinfold Thickness | 4 | 1999 | 49 | 0.120 |
Why?
| | Mitochondrial Proteins | 1 | 2016 | 240 | 0.110 |
Why?
| | Rejuvenation | 1 | 2014 | 18 | 0.110 |
Why?
| | Neurons | 2 | 1995 | 1454 | 0.110 |
Why?
| | Nutritional Status | 1 | 2016 | 328 | 0.110 |
Why?
| | Mobility Limitation | 1 | 2014 | 62 | 0.110 |
Why?
| | Liver | 3 | 2017 | 1846 | 0.110 |
Why?
| | Glomerular Filtration Rate | 1 | 2017 | 691 | 0.110 |
Why?
| | Cell Cycle | 1 | 2016 | 587 | 0.110 |
Why?
| | Plasma Volume | 3 | 2002 | 19 | 0.110 |
Why?
| | Disease Models, Animal | 3 | 2015 | 4044 | 0.110 |
Why?
| | Epidemiology | 1 | 2013 | 15 | 0.110 |
Why?
| | Program Evaluation | 1 | 2018 | 878 | 0.110 |
Why?
| | Administration, Cutaneous | 1 | 2013 | 130 | 0.110 |
Why?
| | Plethysmography | 4 | 2007 | 110 | 0.110 |
Why?
| | Multivariate Analysis | 2 | 2012 | 1510 | 0.100 |
Why?
| | Cardiotonic Agents | 1 | 2014 | 128 | 0.100 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 1994 | 127 | 0.100 |
Why?
| | Absorptiometry, Photon | 2 | 2012 | 250 | 0.100 |
Why?
| | Statistics as Topic | 2 | 2011 | 306 | 0.100 |
Why?
| | Respiratory Mechanics | 1 | 1993 | 65 | 0.100 |
Why?
| | Body Temperature | 5 | 1991 | 216 | 0.100 |
Why?
| | Diabetic Angiopathies | 1 | 2015 | 264 | 0.100 |
Why?
| | Administration, Sublingual | 1 | 2012 | 16 | 0.100 |
Why?
| | Prospective Studies | 6 | 2021 | 7131 | 0.100 |
Why?
| | Pyrogallol | 1 | 2012 | 3 | 0.100 |
Why?
| | Hypotension | 1 | 1993 | 118 | 0.100 |
Why?
| | Catecholamines | 5 | 1996 | 97 | 0.100 |
Why?
| | Mental Processes | 1 | 1992 | 37 | 0.100 |
Why?
| | Aminoimidazole Carboxamide | 1 | 2012 | 11 | 0.100 |
Why?
| | Ribonucleotides | 1 | 2012 | 26 | 0.100 |
Why?
| | Pulmonary Gas Exchange | 4 | 2007 | 119 | 0.100 |
Why?
| | Cerebrovascular Circulation | 2 | 2025 | 224 | 0.100 |
Why?
| | Waist Circumference | 1 | 2012 | 138 | 0.100 |
Why?
| | Hysterectomy | 1 | 2012 | 118 | 0.090 |
Why?
| | Naphthols | 1 | 2011 | 8 | 0.090 |
Why?
| | Nitroso Compounds | 1 | 2011 | 5 | 0.090 |
Why?
| | Receptors, Adrenergic, beta-3 | 1 | 2011 | 4 | 0.090 |
Why?
| | Myography | 1 | 2011 | 4 | 0.090 |
Why?
| | Retrospective Studies | 4 | 2022 | 14675 | 0.090 |
Why?
| | Metabolism | 2 | 2001 | 39 | 0.090 |
Why?
| | Least-Squares Analysis | 1 | 2011 | 72 | 0.090 |
Why?
| | Forkhead Box Protein O3 | 1 | 2011 | 15 | 0.090 |
Why?
| | Chemokine CCL2 | 1 | 2011 | 124 | 0.090 |
Why?
| | Glucose Tolerance Test | 3 | 2018 | 357 | 0.090 |
Why?
| | 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2010 | 18 | 0.090 |
Why?
| | Diastole | 3 | 2003 | 152 | 0.090 |
Why?
| | United States | 3 | 2020 | 14110 | 0.090 |
Why?
| | Connective Tissue | 1 | 2010 | 38 | 0.090 |
Why?
| | Endorphins | 1 | 1990 | 8 | 0.090 |
Why?
| | Mice, Inbred Strains | 1 | 2011 | 408 | 0.090 |
Why?
| | Oxidation-Reduction | 1 | 2014 | 1018 | 0.090 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2010 | 56 | 0.090 |
Why?
| | Benzamides | 1 | 2011 | 195 | 0.090 |
Why?
| | Receptors, Calcitriol | 1 | 2010 | 54 | 0.090 |
Why?
| | Caspases | 1 | 2011 | 249 | 0.090 |
Why?
| | Communication | 1 | 2016 | 844 | 0.090 |
Why?
| | Decompression | 1 | 1990 | 2 | 0.090 |
Why?
| | Phosphoproteins | 1 | 2012 | 333 | 0.090 |
Why?
| | Fibronectins | 1 | 2010 | 119 | 0.080 |
Why?
| | Lipoproteins, HDL | 3 | 1984 | 85 | 0.080 |
Why?
| | Follow-Up Studies | 2 | 2018 | 4961 | 0.080 |
Why?
| | Prediabetic State | 1 | 2013 | 245 | 0.080 |
Why?
| | Curriculum | 1 | 2016 | 929 | 0.080 |
Why?
| | Phenotype | 2 | 2024 | 3084 | 0.080 |
Why?
| | Diet Records | 1 | 2009 | 78 | 0.080 |
Why?
| | Prognosis | 1 | 2018 | 3830 | 0.080 |
Why?
| | Subclavian Artery | 1 | 1989 | 30 | 0.080 |
Why?
| | Cyclooxygenase 1 | 1 | 2009 | 26 | 0.080 |
Why?
| | Receptor, Endothelin A | 1 | 2009 | 63 | 0.080 |
Why?
| | Acclimatization | 1 | 1990 | 161 | 0.080 |
Why?
| | Sex Factors | 2 | 2011 | 1965 | 0.080 |
Why?
| | Leukocyte Count | 1 | 2010 | 328 | 0.080 |
Why?
| | Carotid Sinus | 1 | 1988 | 2 | 0.080 |
Why?
| | Probability | 1 | 2010 | 314 | 0.080 |
Why?
| | Rats, Sprague-Dawley | 2 | 2010 | 2321 | 0.080 |
Why?
| | Arrhythmia, Sinus | 1 | 1988 | 3 | 0.080 |
Why?
| | Homeostasis | 3 | 2021 | 613 | 0.080 |
Why?
| | Blood Pressure Determination | 1 | 2010 | 150 | 0.080 |
Why?
| | Sulfaphenazole | 1 | 2008 | 3 | 0.080 |
Why?
| | Cytochrome P-450 CYP2C9 | 1 | 2008 | 20 | 0.080 |
Why?
| | omega-N-Methylarginine | 1 | 2008 | 26 | 0.080 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2010 | 255 | 0.080 |
Why?
| | Biomechanical Phenomena | 1 | 2012 | 786 | 0.080 |
Why?
| | Tetralogy of Fallot | 1 | 1989 | 79 | 0.080 |
Why?
| | Propranolol | 4 | 2001 | 49 | 0.070 |
Why?
| | Diet, High-Fat | 2 | 2021 | 240 | 0.070 |
Why?
| | Aortic Coarctation | 1 | 1989 | 82 | 0.070 |
Why?
| | Leukocytes | 1 | 2010 | 303 | 0.070 |
Why?
| | Calorimetry, Indirect | 2 | 2005 | 80 | 0.070 |
Why?
| | Estrogen Receptor alpha | 1 | 2009 | 135 | 0.070 |
Why?
| | Interferon-gamma | 1 | 2011 | 766 | 0.070 |
Why?
| | Microscopy, Fluorescence | 1 | 2009 | 405 | 0.070 |
Why?
| | Hyperemia | 1 | 1988 | 48 | 0.070 |
Why?
| | Vasoconstrictor Agents | 2 | 2007 | 131 | 0.070 |
Why?
| | Databases, Factual | 1 | 2013 | 1300 | 0.070 |
Why?
| | Telomere | 1 | 2010 | 231 | 0.070 |
Why?
| | Hyperoxia | 2 | 1999 | 97 | 0.070 |
Why?
| | Catalase | 1 | 2007 | 123 | 0.070 |
Why?
| | Electrophysiology | 3 | 1993 | 207 | 0.070 |
Why?
| | Kinetics | 3 | 1997 | 1634 | 0.070 |
Why?
| | Amidohydrolases | 1 | 2006 | 30 | 0.070 |
Why?
| | Data Interpretation, Statistical | 1 | 2008 | 341 | 0.070 |
Why?
| | Gene Expression | 1 | 2011 | 1487 | 0.070 |
Why?
| | Severity of Illness Index | 2 | 2016 | 2785 | 0.060 |
Why?
| | Hormones | 2 | 2002 | 140 | 0.060 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2007 | 111 | 0.060 |
Why?
| | Body Fat Distribution | 1 | 2005 | 49 | 0.060 |
Why?
| | Hematocrit | 2 | 1997 | 94 | 0.060 |
Why?
| | Codon | 1 | 2005 | 88 | 0.060 |
Why?
| | Fibroblasts | 1 | 2010 | 953 | 0.060 |
Why?
| | Adrenergic beta-Antagonists | 3 | 2001 | 320 | 0.060 |
Why?
| | Heart Ventricles | 3 | 2003 | 782 | 0.060 |
Why?
| | Dihydroxyphenylalanine | 2 | 1995 | 9 | 0.060 |
Why?
| | Methoxyhydroxyphenylglycol | 2 | 1995 | 13 | 0.060 |
Why?
| | Middle Cerebral Artery | 1 | 2025 | 45 | 0.060 |
Why?
| | Vital Capacity | 2 | 2000 | 289 | 0.060 |
Why?
| | Erythrocyte Volume | 2 | 1994 | 6 | 0.060 |
Why?
| | Vasopressins | 1 | 2005 | 64 | 0.060 |
Why?
| | Thigh | 2 | 2003 | 54 | 0.060 |
Why?
| | Calorimetry | 1 | 2004 | 67 | 0.060 |
Why?
| | Recombinant Proteins | 2 | 2018 | 1314 | 0.060 |
Why?
| | Osmolar Concentration | 3 | 2001 | 166 | 0.060 |
Why?
| | Postprandial Period | 1 | 2004 | 103 | 0.060 |
Why?
| | Cell Proliferation | 1 | 2011 | 2381 | 0.060 |
Why?
| | Up-Regulation | 1 | 2007 | 856 | 0.060 |
Why?
| | Stroke | 2 | 2011 | 1119 | 0.050 |
Why?
| | Stem Cells | 1 | 2008 | 585 | 0.050 |
Why?
| | Elastic Modulus | 1 | 2024 | 123 | 0.050 |
Why?
| | RNA, Messenger | 1 | 2011 | 2732 | 0.050 |
Why?
| | Mice, Transgenic | 2 | 2019 | 2107 | 0.050 |
Why?
| | Macrophages | 1 | 2011 | 1482 | 0.050 |
Why?
| | Powders | 1 | 2023 | 42 | 0.050 |
Why?
| | Butanols | 1 | 2022 | 8 | 0.050 |
Why?
| | T-Lymphocytes | 1 | 2011 | 1928 | 0.050 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2023 | 121 | 0.050 |
Why?
| | Femur | 2 | 2001 | 247 | 0.050 |
Why?
| | Biology | 1 | 2023 | 83 | 0.050 |
Why?
| | Evans Blue | 1 | 2002 | 7 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 1 | 2012 | 2551 | 0.050 |
Why?
| | Electromyography | 3 | 1989 | 380 | 0.050 |
Why?
| | Phenols | 1 | 2023 | 97 | 0.050 |
Why?
| | Rats, Inbred Strains | 3 | 1991 | 366 | 0.050 |
Why?
| | Ganglia, Autonomic | 1 | 2001 | 2 | 0.050 |
Why?
| | Phentolamine | 1 | 2001 | 14 | 0.050 |
Why?
| | Mesentery | 1 | 2002 | 47 | 0.050 |
Why?
| | Ischemia | 5 | 1994 | 399 | 0.050 |
Why?
| | Infusions, Intra-Arterial | 1 | 2001 | 54 | 0.050 |
Why?
| | Adrenergic alpha-Antagonists | 1 | 2001 | 34 | 0.050 |
Why?
| | Respiratory Function Tests | 2 | 1994 | 598 | 0.050 |
Why?
| | Men | 1 | 2001 | 22 | 0.050 |
Why?
| | Genotype | 1 | 2007 | 1839 | 0.050 |
Why?
| | Acarbose | 1 | 2021 | 2 | 0.050 |
Why?
| | Lactic Acid | 4 | 1995 | 296 | 0.050 |
Why?
| | Tidal Volume | 2 | 1993 | 83 | 0.050 |
Why?
| | Drugs, Chinese Herbal | 1 | 2021 | 14 | 0.050 |
Why?
| | Models, Biological | 2 | 2004 | 1716 | 0.050 |
Why?
| | Neurons, Afferent | 2 | 1993 | 88 | 0.050 |
Why?
| | Blood Viscosity | 1 | 2001 | 16 | 0.050 |
Why?
| | Clinical Trials as Topic | 2 | 2014 | 1015 | 0.040 |
Why?
| | Thoracic Arteries | 1 | 2000 | 4 | 0.040 |
Why?
| | Catheterization | 1 | 2001 | 178 | 0.040 |
Why?
| | Mouth | 1 | 2021 | 82 | 0.040 |
Why?
| | Pressure | 1 | 2001 | 239 | 0.040 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 1 | 2020 | 44 | 0.040 |
Why?
| | Hypertrophy | 1 | 2001 | 120 | 0.040 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2015 | 2440 | 0.040 |
Why?
| | Organ Size | 2 | 2016 | 450 | 0.040 |
Why?
| | Mexico | 1 | 2001 | 190 | 0.040 |
Why?
| | Thinness | 1 | 2000 | 90 | 0.040 |
Why?
| | Stress, Mechanical | 2 | 2001 | 470 | 0.040 |
Why?
| | Corticotropin-Releasing Hormone | 2 | 1991 | 61 | 0.040 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2003 | 390 | 0.040 |
Why?
| | Rats, Inbred F344 | 2 | 1990 | 251 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2005 | 1974 | 0.040 |
Why?
| | NADP | 1 | 2019 | 44 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2024 | 620 | 0.040 |
Why?
| | Head-Down Tilt | 1 | 1999 | 6 | 0.040 |
Why?
| | Myocardial Infarction | 2 | 2005 | 1036 | 0.040 |
Why?
| | Antihypertensive Agents | 1 | 2022 | 489 | 0.040 |
Why?
| | Receptors, Interleukin-1 Type I | 1 | 2018 | 24 | 0.040 |
Why?
| | Hyperinsulinism | 1 | 2019 | 119 | 0.040 |
Why?
| | Prevalence | 2 | 2005 | 2576 | 0.040 |
Why?
| | Immunity, Innate | 1 | 2024 | 814 | 0.040 |
Why?
| | Oncogene Protein p21(ras) | 1 | 2017 | 16 | 0.040 |
Why?
| | Biological Transport | 1 | 2019 | 397 | 0.040 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 1998 | 86 | 0.040 |
Why?
| | Acute Disease | 1 | 2000 | 981 | 0.040 |
Why?
| | Mathematics | 2 | 1996 | 103 | 0.040 |
Why?
| | Automation | 1 | 1997 | 83 | 0.040 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 1998 | 83 | 0.040 |
Why?
| | Signal Processing, Computer-Assisted | 1 | 1998 | 143 | 0.040 |
Why?
| | Rotarod Performance Test | 1 | 2017 | 15 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2001 | 1200 | 0.030 |
Why?
| | Echocardiography | 2 | 2005 | 640 | 0.030 |
Why?
| | Splanchnic Circulation | 2 | 1999 | 10 | 0.030 |
Why?
| | Cell Respiration | 1 | 2017 | 97 | 0.030 |
Why?
| | Adenylate Kinase | 1 | 2016 | 26 | 0.030 |
Why?
| | Weight Lifting | 3 | 1988 | 34 | 0.030 |
Why?
| | Muscle Development | 1 | 1997 | 103 | 0.030 |
Why?
| | Myoblasts | 1 | 2017 | 80 | 0.030 |
Why?
| | Body Height | 1 | 1997 | 192 | 0.030 |
Why?
| | Tissue Plasminogen Activator | 1 | 1998 | 226 | 0.030 |
Why?
| | Receptors, Interleukin-1 | 1 | 2017 | 225 | 0.030 |
Why?
| | Oxidative Phosphorylation | 1 | 2017 | 186 | 0.030 |
Why?
| | Longitudinal Studies | 2 | 2019 | 2691 | 0.030 |
Why?
| | Pain | 2 | 1992 | 765 | 0.030 |
Why?
| | Resilience, Psychological | 1 | 2017 | 119 | 0.030 |
Why?
| | Cholesterol, HDL | 3 | 1984 | 203 | 0.030 |
Why?
| | Indicator Dilution Techniques | 1 | 1995 | 11 | 0.030 |
Why?
| | Haplorhini | 1 | 2015 | 57 | 0.030 |
Why?
| | Menstruation | 1 | 1995 | 44 | 0.030 |
Why?
| | Receptors, Leptin | 1 | 2015 | 23 | 0.030 |
Why?
| | Protein Kinases | 1 | 2017 | 307 | 0.030 |
Why?
| | Autonomic Fibers, Postganglionic | 1 | 1994 | 1 | 0.030 |
Why?
| | Spectrophotometry | 1 | 1994 | 59 | 0.030 |
Why?
| | Median Nerve | 1 | 1994 | 22 | 0.030 |
Why?
| | Neurotransmitter Agents | 1 | 1995 | 82 | 0.030 |
Why?
| | Homozygote | 1 | 2015 | 192 | 0.030 |
Why?
| | Mice, Mutant Strains | 1 | 2015 | 295 | 0.030 |
Why?
| | Dilatation, Pathologic | 1 | 2014 | 61 | 0.030 |
Why?
| | Reproducibility of Results | 2 | 2003 | 3069 | 0.030 |
Why?
| | Gated Blood-Pool Imaging | 1 | 1994 | 5 | 0.030 |
Why?
| | Heterozygote | 1 | 2015 | 270 | 0.030 |
Why?
| | Educational Measurement | 1 | 2016 | 264 | 0.030 |
Why?
| | Point Mutation | 1 | 2015 | 227 | 0.030 |
Why?
| | Health | 1 | 2014 | 74 | 0.030 |
Why?
| | Activating Transcription Factor 6 | 1 | 2013 | 17 | 0.030 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2016 | 385 | 0.030 |
Why?
| | eIF-2 Kinase | 1 | 2013 | 30 | 0.030 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2017 | 513 | 0.030 |
Why?
| | Disability Evaluation | 1 | 2015 | 291 | 0.030 |
Why?
| | Lipopolysaccharides | 1 | 2017 | 884 | 0.030 |
Why?
| | Heart-Lung Transplantation | 1 | 1993 | 10 | 0.030 |
Why?
| | Denervation | 1 | 1993 | 21 | 0.030 |
Why?
| | Reflex, Stretch | 1 | 1993 | 10 | 0.030 |
Why?
| | Venous Pressure | 1 | 1992 | 9 | 0.030 |
Why?
| | Endoribonucleases | 1 | 2013 | 70 | 0.030 |
Why?
| | Microbiota | 1 | 2021 | 726 | 0.030 |
Why?
| | Chemoreceptor Cells | 1 | 1993 | 55 | 0.030 |
Why?
| | Synaptic Transmission | 1 | 1995 | 261 | 0.030 |
Why?
| | Fingers | 1 | 2013 | 87 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 2016 | 585 | 0.030 |
Why?
| | Age of Onset | 1 | 2014 | 499 | 0.030 |
Why?
| | Tissue Distribution | 1 | 1993 | 297 | 0.030 |
Why?
| | Skin Temperature | 1 | 1992 | 31 | 0.020 |
Why?
| | Ovariectomy | 1 | 2012 | 139 | 0.020 |
Why?
| | Renal Circulation | 1 | 1991 | 57 | 0.020 |
Why?
| | Task Performance and Analysis | 1 | 1992 | 174 | 0.020 |
Why?
| | Cardiography, Impedance | 1 | 1991 | 8 | 0.020 |
Why?
| | Cell Line | 1 | 2017 | 2786 | 0.020 |
Why?
| | Endoplasmic Reticulum | 1 | 2013 | 263 | 0.020 |
Why?
| | Inspiratory Capacity | 1 | 1990 | 2 | 0.020 |
Why?
| | Metformin | 1 | 2014 | 312 | 0.020 |
Why?
| | Acupuncture Therapy | 1 | 1990 | 19 | 0.020 |
Why?
| | Precision Medicine | 1 | 2014 | 388 | 0.020 |
Why?
| | Arousal | 1 | 1991 | 151 | 0.020 |
Why?
| | Blood Pressure Monitors | 1 | 1989 | 3 | 0.020 |
Why?
| | Anorexia Nervosa | 1 | 1990 | 75 | 0.020 |
Why?
| | Lipoproteins | 2 | 1988 | 172 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2011 | 817 | 0.020 |
Why?
| | Total Lung Capacity | 1 | 1988 | 33 | 0.020 |
Why?
| | Fever | 1 | 1990 | 303 | 0.020 |
Why?
| | Menstrual Cycle | 1 | 2009 | 124 | 0.020 |
Why?
| | Neural Inhibition | 1 | 1989 | 152 | 0.020 |
Why?
| | Postoperative Period | 1 | 1989 | 325 | 0.020 |
Why?
| | Saponins | 1 | 1988 | 8 | 0.020 |
Why?
| | Digoxin | 1 | 1988 | 30 | 0.020 |
Why?
| | Ultrasonography, Doppler, Duplex | 1 | 2007 | 43 | 0.020 |
Why?
| | Adrenergic Fibers | 1 | 1987 | 4 | 0.020 |
Why?
| | Child | 3 | 1997 | 20961 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2009 | 1067 | 0.020 |
Why?
| | Pain Management | 1 | 1990 | 322 | 0.020 |
Why?
| | Depressive Disorder | 1 | 1990 | 363 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2007 | 201 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2013 | 1121 | 0.020 |
Why?
| | Kidney Diseases | 1 | 2011 | 377 | 0.020 |
Why?
| | Forced Expiratory Volume | 1 | 1988 | 509 | 0.020 |
Why?
| | Down-Regulation | 1 | 2009 | 642 | 0.020 |
Why?
| | Fatigue | 1 | 1988 | 322 | 0.020 |
Why?
| | Environmental Exposure | 1 | 1991 | 478 | 0.020 |
Why?
| | Heart Block | 1 | 1986 | 41 | 0.020 |
Why?
| | Blood Proteins | 1 | 1988 | 239 | 0.020 |
Why?
| | Syncope | 1 | 1986 | 50 | 0.020 |
Why?
| | Peptide Fragments | 1 | 1990 | 698 | 0.020 |
Why?
| | Feedback | 1 | 2005 | 160 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2011 | 1381 | 0.010 |
Why?
| | Hemostatics | 1 | 2005 | 48 | 0.010 |
Why?
| | Anabolic Agents | 1 | 1984 | 12 | 0.010 |
Why?
| | Dogs | 1 | 2005 | 377 | 0.010 |
Why?
| | Mice, Knockout | 1 | 2011 | 2811 | 0.010 |
Why?
| | Affect | 1 | 2007 | 288 | 0.010 |
Why?
| | Drug Tolerance | 1 | 1984 | 82 | 0.010 |
Why?
| | Arrhythmias, Cardiac | 1 | 1986 | 318 | 0.010 |
Why?
| | C-Peptide | 1 | 1984 | 163 | 0.010 |
Why?
| | Methods | 1 | 1983 | 65 | 0.010 |
Why?
| | Work Capacity Evaluation | 1 | 2002 | 12 | 0.010 |
Why?
| | Androgens | 1 | 1984 | 174 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1983 | 175 | 0.010 |
Why?
| | Wrestling | 1 | 1982 | 2 | 0.010 |
Why?
| | Motivation | 1 | 2007 | 544 | 0.010 |
Why?
| | Heart Arrest | 1 | 1986 | 328 | 0.010 |
Why?
| | Gymnastics | 1 | 1982 | 22 | 0.010 |
Why?
| | Nutritional Physiological Phenomena | 1 | 2001 | 53 | 0.010 |
Why?
| | Sodium Chloride | 1 | 2001 | 142 | 0.010 |
Why?
| | Efferent Pathways | 2 | 1992 | 16 | 0.010 |
Why?
| | Renal Veins | 1 | 1999 | 16 | 0.010 |
Why?
| | Jugular Veins | 1 | 1999 | 39 | 0.010 |
Why?
| | Models, Cardiovascular | 1 | 2000 | 196 | 0.010 |
Why?
| | Metabolic Clearance Rate | 1 | 1998 | 108 | 0.010 |
Why?
| | Oscillometry | 1 | 1998 | 37 | 0.010 |
Why?
| | Adrenal Cortex Hormones | 1 | 2001 | 527 | 0.010 |
Why?
| | Self Concept | 1 | 1996 | 238 | 0.010 |
Why?
| | Injections, Intraventricular | 1 | 1990 | 53 | 0.010 |
Why?
| | Pain Measurement | 1 | 1992 | 491 | 0.010 |
Why?
| | Pancreatic Hormones | 1 | 1988 | 3 | 0.000 |
Why?
| | Thyroid Hormones | 1 | 1988 | 54 | 0.000 |
Why?
| | Cardenolides | 1 | 1988 | 1 | 0.000 |
Why?
| | Glycerol | 1 | 1988 | 87 | 0.000 |
Why?
| | Growth Hormone | 1 | 1988 | 96 | 0.000 |
Why?
| | Fatty Acids, Nonesterified | 1 | 1988 | 159 | 0.000 |
Why?
| | Insulin-Like Growth Factor I | 1 | 1988 | 308 | 0.000 |
Why?
| | Differential Threshold | 1 | 1985 | 5 | 0.000 |
Why?
| | Maximal Voluntary Ventilation | 1 | 1985 | 8 | 0.000 |
Why?
| | Risk | 1 | 1987 | 873 | 0.000 |
Why?
| | Ammonia | 1 | 1984 | 62 | 0.000 |
Why?
| | Action Potentials | 1 | 1987 | 472 | 0.000 |
Why?
| | Bicycling | 1 | 1985 | 118 | 0.000 |
Why?
| | Testosterone | 1 | 1984 | 383 | 0.000 |
Why?
| | Substance-Related Disorders | 1 | 1984 | 1023 | 0.000 |
Why?
|
|
Seals's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|